Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of iparomlimab + tuvonralimab + apatinib + capecitabine in previously treated advanced esophageal cancer
ChiCTR2500100119Phase 4Not yet recruiting
- Sponsor
- Taizhou People's Hospital
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab, tuvonralimab, Rivoceranib and capecitabine in esophageal cancer, sponsored by Taizhou People's Hospital. Primary endpoint: Objective response rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabRivoceranibcapecitabine
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2500100119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100119.